Qu Biologics Completes Enrollment of Randomized Clinical Trial in Crohn's Disease

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 24, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted organ, announced that it has completed enrollment of its QBECO-01 Crohn's disease clinical trial, with top-line data expected in late 1Q 2016.

Qu Biologics' QBECO-01 is a 68-patient Phase 1/2 randomized, double-blind, placebo-controlled clinical trial in patients with moderate-to-severe Crohn's disease. The investigators in the study include gastroenterologists Dr. Brian Bressler (Gastrointestinal Research Institute, Vancouver, BC), Dr. Richard Fedorak (University of Alberta, Edmonton, AB), Dr. John Marshall (McMaster University, Hamilton, ON), Dr. Remo Panaccione (University of Calgary, Calgary, AB) and Dr. Jeffrey Axler (Toronto Digestive Disease Associates, Toronto, ON).

QBECO SSI, derived from components of inactivated E. coli, is designed to restore normal immune function in the GI tract. Qu Biologics' Founder and CEO, Dr. Hal Gunn, stated, "Completing enrollment in QBECO-01, our lead development program, is a critical milestone for our company. There is a significant unmet need for improved therapies for inflammatory bowel disease (IBD) - Crohn's disease specifically - and we hope that QBECO SSI, which is designed to restore normal immune function rather than simply suppressing the immune system, will offer a superior alternative to existing therapies." He added, "We look forward to unblinding our top-line results in late 1Q 2016, with complete results by mid-2016. Importantly, we recently initiated a complementary open-label Phase 2 study in patients with moderate-to-severe ulcerative colitis, as well as commercial-scale cGMP production of QBECO, laying the groundwork to begin pivotal studies in IBD in 2017."

About Qu Biologics

Qu Biologics develops Site Specific Immunomodulators (SSIs), a novel class of immunotherapies that aim to restore the body's normal immune response. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many illnesses, including cancer and other immune-related diseases such as inflammatory bowel diseases. The company is conducting clinical trials in Crohn's disease, ulcerative colitis and recurrent non-small cell lung cancer to study SSI treatment.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com or www.quibd.com.

Qu Biologics Inc. cautions you that statements included in this release that are not a description of historical facts may contain forward-looking statements. These forward-looking statements are only predictions and may involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.